Buchumschlag

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Na‐Ling Kang, Lu‐Ying Wu, Qi Zheng, Xue‐Ping Yu, Ai‐Rong Hu, Yue Guo, Huan Li, Xiang‐Yang Ye, Qing‐Fa Ruan, Zhong‐Hua Lu, Ling Wu, Wen Jin, Yu‐Rui Liu, Chen Pan, Shan‐Shan Liu, Ji‐Ming Zhang, Jia‐Ji Jiang, Da‐Wu Zeng
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
von: Jianrong Li, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
von: Jing Li, et al.
Veröffentlicht: (2024)

Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling
von: Eunice X. Tan, et al.
Veröffentlicht: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
von: Lisa Sandmann, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
von: Jian Wang, et al.
Veröffentlicht: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
von: Basile Njei, et al.
Veröffentlicht: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
von: Ze‐Hua Zhao, et al.
Veröffentlicht: (2025)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
von: Eunice X. X. Tan, et al.
Veröffentlicht: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
von: Maria Buti, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
von: WenXian OuYang, et al.
Veröffentlicht: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
von: Chen‐Pi Li, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
von: Jung Eun Park, et al.
Veröffentlicht: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
von: Hye Won Lee, et al.
Veröffentlicht: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
von: Yen‐Chun Liu, et al.
Veröffentlicht: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
von: Eiichi Ogawa
Veröffentlicht: (2024)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
von: Hariklia Kranidioti, et al.
Veröffentlicht: (2024)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
von: Xiaosong Li, et al.
Veröffentlicht: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
von: Carolyn Singleton, et al.
Veröffentlicht: (2024)

Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C
von: Nikolaos Papadopoulos, et al.
Veröffentlicht: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
von: Matthew J. Townsend, et al.
Veröffentlicht: (2024)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
von: Julian Hercun, et al.
Veröffentlicht: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
von: Vishnu Girish, et al.
Veröffentlicht: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
von: Elena Vargas‐Accarino, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
von: Ann T. Ma, et al.
Veröffentlicht: (2024)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply
von: Yu Liu, et al.
Veröffentlicht: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
von: Lukas Hartl, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
von: Yu Liu, et al.
Veröffentlicht: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
von: Philip Vutien, et al.
Veröffentlicht: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
von: Min Wu, et al.
Veröffentlicht: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
von: Philippe Sultanik, et al.
Veröffentlicht: (2024)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
von: Ling Yang, et al.
Veröffentlicht: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
von: Chang Liu, et al.
Veröffentlicht: (2026)

Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation
von: Xidi Yang, et al.
Veröffentlicht: (2026)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
von: Yuxin Chen, et al.
Veröffentlicht: (2025)